Jacobs Levy Equity Management
CRBP icon

Jacobs Levy Equity Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Jacobs Levy Equity Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,816
Closed -$117K – 989
2021
Q3 		$117K Buy
+3,816
New +$151K ﹤0.01% 1014
2020
Q3 		– Sell
-3,920
Closed -$987K – 1040
2020
Q2 		$987K Buy
3,920
+2,547
+186% +$515K 0.01% 675
2020
Q1 		$216K Buy
+1,373
New +$232K ﹤0.01% 873

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Jacobs Levy Equity Management's CRBP Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2021, closing a stake of 3,816 shares — an estimated $117K sold.

Jacobs Levy Equity Management first reported a position in CRBP in Q1 2020 and held it in 3 quarters. The position peaked at $987K in Q2 2020. 82 funds tracked by Wall St. Rank hold CRBP as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Corbus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,816 Corbus Pharmaceuticals shares in Q4 2021, an estimated $117K.
  • Jacobs Levy Equity Management first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Corbus Pharmaceuticals position peaked at $987K in Q2 2020.
  • 82 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.